MYO MYOMO, INC.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1369290 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.3%
TTM net income YoY-25.4%
TTM EPS YoY-25.0%
Revenue 3-yr CAGR34.9%
Net income 3-yr CAGR—
Margins
Gross margin70.1%
Operating margin-21.8%
Net margin-33.1%
FCF margin-12.7%
EBITDA margin-18.8%
Returns
ROE-173.5%
ROA-44.4%
ROIC (approx.)-154.0%
Asset turnover1.34x
Leverage & solvency
Liabilities / assets91.9%
Debt / equity4.89x
Current ratio1.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.44x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue-1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $40.93M | $32.55M |
| Cost of revenue | $14.04M | $9.37M |
| Gross profit | $26.89M | $23.19M |
| R&D expense | $6.94M | $4.77M |
| SG&A expense | $13.96M | $12.38M |
| Operating income | -$14.40M | -$6.21M |
| Pretax income | -$15.07M | -$5.82M |
| Income tax | $504,532 | $365,617 |
| Net income | -$15.57M | -$6.18M |
| EBITDA | -$13.54M | -$6.00M |
| EPS (basic) | -0.37 | -0.16 |
| EPS (diluted) | -0.37 | -0.16 |
| Weighted avg. shares (diluted) | 41.86M | 37.76M |
| Balance sheet | ||
| Cash & equivalents | $14.13M | $24.37M |
| Short-term investments | $4.26M | $492,990 |
| Receivables | $4.10M | $3.83M |
| Inventory | $3.12M | $3.17M |
| Current assets | $27.56M | $32.79M |
| PP&E, net | $2.21M | $1.33M |
| Total assets | $38.64M | $42.24M |
| Current liabilities | $8.35M | $10.17M |
| Short-term debt | $0 | $2.95M |
| Long-term debt | $11.22M | $11.22M |
| Total debt | $11.22M | $14.18M |
| Total liabilities | $27.23M | $17.53M |
| Shareholders' equity | $11.40M | $24.71M |
| Net debt | -$2.91M | -$10.20M |
| Shares outstanding | 38.47M | 34.38M |
| Cash flow statement | ||
| Operating cash flow | -$14.51M | -$3.29M |
| Capital expenditure | $1.74M | $1.36M |
| Free cash flow | -$16.25M | -$4.65M |
| Investing cash flow | -$7.06M | $259,981 |
| Financing cash flow | $11.43M | $20.93M |
| Depreciation & amortization | $859,354 | $205,910 |
| Stock-based compensation | $2.08M | $874,438 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.